看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。$ o- R5 n6 X$ l& O: t
4 G" y/ ]4 j. s/ ]! Z% ?7 K
) W$ V. P# }) g# V
Currently available feasibility data for possible combination strategies. . _4 P" |$ w* _ ~4 ]3 ~* l2 v
————————————————————————————————" J7 n( V% z6 n6 V7 e
Combination Feasibility according to preliminary data
: ]4 R9 T3 y/ c( U6 h! v e R+ K8 Q——————————————————————————————————% l1 X- m! |1 E" z: r$ V3 `
Bevacizumab + sorafenib Yes, reduced dose 2 B, M/ t) V( ~4 C' [
Bevacizumab + sunitinib† No
; \+ i. ]& m1 o& t+ w4 K2 SBevacizumab + temsirolimus Yes 8 }4 U* U6 w+ w; x: _2 i- {2 U2 `( {
Bevacizumab + everolimus Yes
4 ~* I9 O( ^, n) q" I! g4 FSorafenib + sunitinib ? $ ^1 j/ k2 ?, `# f+ g0 M
Sorafenib + temsirolimus Yes, reduced dose 4 I) W0 I. y. w+ I, k; R+ M+ {/ U
Sorafenib + everolimus Yes, reduced dose : j5 j, Y) L: m% U
Sunitinib + temsirolimus† No
% ^& q; o3 v- f7 A- YSunitinib + everolimus ? # @" N. ~& a9 h0 D& |2 V
Temsirolimus + everolimus ?
% T# h. U" D) Q8 E- u2 C/ I6 y————————————————————/ O4 s5 [/ P. V- A- v3 m
†Led to US FDA warning." Z0 W+ _. h* V& O# n1 X
?: As yet unattempted combination.4 {$ U# f6 a. M; D) g
|
显身卡
. |4 k) Z, ` K2 n( a
